Genetic polymorphism in β-site amyloid precursor protein-cleaving enzyme 1 affects the structure of medial temporal lobe and cognition in Alzheimer's disease: an exploratory study
- PMID: 39733191
- DOI: 10.1007/s00406-024-01953-2
Genetic polymorphism in β-site amyloid precursor protein-cleaving enzyme 1 affects the structure of medial temporal lobe and cognition in Alzheimer's disease: an exploratory study
Abstract
The β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) gene polymorphism (rs638405) has been widely reported to be associated with Alzheimer's disease (AD) risk. However, studies on the relationship between BACE1 gene polymorphism (rs638405), brain volume, and cognition in AD patients remain scarce. To investigate the effect of genetic polymorphism in BACE1 on gray matter volume (GMV) and cognition in AD, this study recruited 111 cognitively unimpaired (CU) controls and 144 AD patients. The effect of BACE1 rs638405 polymorphism on cognition was explored in CU and AD groups. Then the interaction effect of the diagnosis and BACE1 rs638405 polymorphism on GMV was performed, following the post-hoc analysis of regions of interest (ROIs) in interaction analysis. Mediation analysis was used to elucidate the relationship among genotypes, ROIs and cognition. BACE1 rs638405 G carriers (BACE1 G+) showed significantly lower scores in global cognition and memory function than noncarriers (BACE1 G-) in AD group. Genotypes (G+/G-) and diagnosis (CU/AD) have interaction on GMV of medial temporal lobe (MTL) including the left parahippocampus and right hippocampus. Post-hoc analysis revealed that BACE1 G+ exhibited significantly lower GMV in ROIs compared to BACE1 G- in AD. Finally, mediation analysis further demonstrated that the GMV of ROIs mediated the effect of BACE1 rs638405 polymorphism on cognition in AD. Our results emphasize the BACE1 rs638405 gene polymorphisms may affect the GMV of MTL and cognition in AD, deepening the understanding of AD pathogenesis.
Keywords: Alzheimer’s disease; BACE1; Gray matter; Memory function.
© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: We have no conflict of interest to declare.
Similar articles
-
Relationship between the polymorphism in exon 5 of BACE1 gene and Alzheimer's disease.Aging Clin Exp Res. 2017 Apr;29(2):105-113. doi: 10.1007/s40520-016-0539-0. Epub 2016 Feb 4. Aging Clin Exp Res. 2017. PMID: 26846559 Review.
-
Association of G/C (rs638405) Polymorphism in β-secretase Gene with Alzheimer's Disease.Avicenna J Med Biotechnol. 2018 Oct-Dec;10(4):242-247. Avicenna J Med Biotechnol. 2018. PMID: 30555657 Free PMC article.
-
Association of BACE1 Gene Polymorphism with Cerebellar Volume but Not Cognitive Function in Normal Individuals.Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):632-7. doi: 10.1159/000345980. Epub 2012 Dec 15. Dement Geriatr Cogn Dis Extra. 2012. PMID: 23341828 Free PMC article.
-
Meta-analysis of BACE1 gene rs638405 polymorphism and the risk of Alzheimer's disease in Caucasion and Asian population.Neurosci Lett. 2016 Mar 11;616:189-96. doi: 10.1016/j.neulet.2016.01.059. Epub 2016 Jan 30. Neurosci Lett. 2016. PMID: 26828303
-
Beta-site APP-cleaving Enzyme-1 Inhibitory Role of Natural Flavonoids in the Treatment of Alzheimer's Disease.Cent Nerv Syst Agents Med Chem. 2025;25(1):39-48. doi: 10.2174/0118715249315049240710063455. Cent Nerv Syst Agents Med Chem. 2025. PMID: 39005132 Review.
Cited by
-
Arketamine: a scoping review of its use in humans.Eur Arch Psychiatry Clin Neurosci. 2025 Aug;275(5):1317-1332. doi: 10.1007/s00406-024-01945-2. Epub 2024 Dec 16. Eur Arch Psychiatry Clin Neurosci. 2025. PMID: 39680139
References
-
- Scheltens P, De Strooper B, Kivipelto M et al (2021) Alzheimer’s disease. Lancet 397:1577–1590. https://doi.org/10.1016/s0140-6736(20)32205-4 - DOI - PubMed - PMC
-
- Yankner BA (1996) Mechanisms of neuronal degeneration in Alzheimer’s disease. Neuron 16:921–932. https://doi.org/10.1016/s0896-6273(00)80115-4 - DOI - PubMed
-
- Vassar R (2004) BACE1: the beta-secretase enzyme in Alzheimer’s disease. J Mol Neurosci 23:105–114. https://doi.org/10.1385/jmn:23:1-2:105 - DOI - PubMed
-
- Hampel H, Vassar R, De Strooper B et al (2021) The β-secretase BACE1 in Alzheimer’s disease. Biol Psychiatry 89:745–756. https://doi.org/10.1016/j.biopsych.2020.02.001 - DOI - PubMed
-
- Cai H, Wang Y, McCarthy D et al (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4:233–234. https://doi.org/10.1038/85064 - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources